Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/10/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
6104(c) 6137(c) 6198(c) 6194(c) 6215(c) Last
832 707 1 548 857 1 977 024 1 499 292 1 581 686 Volume
+1.26% +0.54% +0.99% -0.06% +0.34% Change
More quotes
Financials (USD)
Sales 2019 23 593 M
EBIT 2019 6 356 M
Net income 2019 2 672 M
Debt 2019 12 282 M
Yield 2019 3,60%
Sales 2020 26 011 M
EBIT 2020 7 440 M
Net income 2020 3 790 M
Debt 2020 12 292 M
Yield 2020 3,60%
P/E ratio 2019 38,05
P/E ratio 2020 26,99
EV / Sales2019 4,78x
EV / Sales2020 4,33x
Capitalization 100 B
More Financials
Company
AstraZeneca is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - cardiovascular and metabolic diseases (32.3%); - respiratory diseases (20.9%); - oncology (17.9%); - other (18.5%): inflammatory and autoimmune diseases, neurological diseases,... 
Sector
Pharmaceuticals
Calendar
06/16Presentation
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
07:01aASTRAZENECA : CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patien..
BU
03:34aASTRAZENECA : Calquence significantly prolonged the time patients lived without ..
PU
06/14ASTRAZENECA : LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in P..
BU
06/14ASTRAZENECA : Lokelma demonstrated efficacy in treating hyperkalaemia in patient..
PU
06/12ASTRAZENECA : Publication of a Prospectus
AQ
06/10ASTRAZENECA : Farxiga Reduced Progression of Kidney Disease or Renal Death in Ty..
DJ
06/10ASTRAZENECA : FARXIGA Study Showed Reduced Progression of Kidney Disease or Rena..
BU
06/10ASTRAZENECA : Diabetes Drug Helps Prevent Kidney Complications
DJ
06/07France's Sanofi bets on new CEO to drive sluggish drug sales
RE
06/07Sanofi CEO Olivier Brandicourt Retires; Paul Hudson Named Replacement -- Upda..
DJ
More news
Analyst Recommendations on ASTRAZENECA
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aDrug Firms Sue Over Ad Rule -- WSJ
DJ
06/14Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy--Update
DJ
06/14BAYER : Deutsche Bahn to Phase out Glyphosate -WirtschaftWoche
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy
DJ
More sector news : Pharmaceuticals - NEC
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,2 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA5.82%98 485
JOHNSON & JOHNSON9.04%348 981
PFIZER-2.63%233 072
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893
MERCK AND COMPANY8.34%206 641